NCT03531320View on ClinicalTrials.gov

Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 6, 2018

Primary Completion Date

December 28, 2020

Study Completion Date

December 29, 2020

Conditions
Gastrointestinal CancerBiliary Tract Cancer
Interventions
DRUG

D07001-softgel capsules

Active Ingredient:Gemcitabine hydrochloride

Trial Locations (4)

100

National Taiwan University Hospital, Taipei

404

China Medical University Hospital, Taichung

704

National Cheng-Kung University Hospital, Tainan City

11217

Taipei Veterans General Hospital, Taipei

Sponsors

Lead Sponsor

InnoPharmax Inc.
All Listed Sponsors
lead

InnoPharmax Inc.

INDUSTRY

NCT03531320 - Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase | Biotech Hunter | Biotech Hunter